Business
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO™
About this update from Harrow, Inc.
[{"type":"text","content":" NASHVILLE, Tenn.--(BUSINESS WIRE)--\nHarrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commercial team will be available to discuss IHEEZO and the entire Harrow portfolio of ophthalmic pharmaceutical products at ASCRS booth #2237.\n\n\nIHEEZO is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. IHEEZO, which has been issued a J‑Code (J2403) and transitional pass-through reimbursement status by the Centers for Medicare & Medicaid Services (CMS), represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.\n\n\nIHEEZO Launch Events\n\n\n\nDr. Richard L. Lindstrom will be making a presentation titled, Prospective, Randomized Comparison of Chloroprocaine 3% Gel and Tetracaine 0.5% Solution for Cataract Surgery Anesthesia. The presentation is scheduled during the Medications (Preoperative, Postoperative, Intraoperative) session on Sunday, May 7th, beginning at 3:40 p.m. PT in the SDCC, Upper Level, Room 5A.\n\n\n\n\nDr. William Wiley will speak about his experience using IHEEZO during a booth talk scheduled to begin at 1:30 p.m. PT at Harrow’s booth #2237 on Saturday, May 6th.\n\n\n\n\nHarrow will host the “Harrow Brings Nashville to San Diego” IHEEZO Launch Event at the Hard Rock Hotel in downtown San Diego from 5:30-7:30 p.m. on Saturday, May 6th.\nTo attend the event and learn more about IHEEZO, please register by clicking here.\n\n\n\nAll educational content of the ASCRS Annual Meeting is planned by its program committee. ASCRS does not endorse, promote, approve, or recommend using any products, devices, or services.\n\n\nAbout Harrow\n\n\nHarrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and ...